Dienogest-Ethinyl Estradiol (test product)

PreclinicalSmall molecule

Dienogest-Ethinyl Estradiol (test product) is one of 22 small molecule programs targeting Single Dose. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Single DoseCompleted

Single DosePreclinical

Completed

Competition

Competitive Landscape

26 competitors in Single Dose

#DrugCompanyPhaseTrials

Namenda

AbbVie

Phase 2

2 2

Lioresal

Novartis

Phase 2

1 3

Daliresp

AstraZeneca

Phase 2

1 4

Cialis

Eli Lilly

Phase 1

3 5

Opdivo

Bristol-Myers Squibb

Phase 1

1 6

Acoziborole

DDrugs for Neglected Diseases

Phase 3

1 7

LP-003

LLongbio Pharma

Phase 2

1 8

Psilocybin

COMPASS Pathways

Phase 1

1 9

Avodart

Akero Therapeutics

Preclinical

1 10

Kytril

CConrado Roberto Hoffmann Filho

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Dose1 trial

Bioavailability Study With Oral Single Dose Administration of Ethinylestradiol and Dienogest

Completed·PPharbil Waltrop GmbH·N/A·NCT01600274·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dienogest-Ethinyl Estradiol (test product). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dienogest-Ethinyl Estradiol (test product) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dienogest-Ethinyl Estradiol (test product). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pharbil Waltrop GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPharbil Waltrop GmbH

Dienogest-Ethinyl Estradiol (test product)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Dose1 trial

References

Drug Info

Quick Facts

Related News